0K6R.LSE Neurocrine Biosciences, Inc.

Healthcare Drug Manufacturers - Specialty & Generic London Exchange
- USD
Market cap
-
P/E
208.9x
P/B
-
ROE
18.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0K6R.LSE undervalued?

Graham number

The Graham number of Neurocrine Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neurocrine Biosciences, Inc. fundamental analysis

No fundamental analysis for Neurocrine Biosciences, Inc. yet.

Neurocrine Biosciences, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under th…

Full company profile